Expanding Scalability Potential of T-Cell Therapies with Allogeneic Approaches

  • Supply constraints:
  • autologous vs allogeneic therapy production
  • Allogeneic manufacturing process, scalability considerations, and optimizing patient supply
  • Balancing in-house and external capabilities through strategic partnerships

Amy Gamber
VP, Manufacturing
Atara Biotherapeutics

Amy has been at Atara Biotherapeutics for 5 years. She is currently the Vice President of Manufacturing, which includes External Manufacturing, Material Sciences, and Manufacturing Science and Technology functions. Prior to her current role, she led the joint team that transitioned the commercialization of the first approved allogeneic T-cell therapy to Atara’s strategic partner, Pierre Fabre. Amy has broad operations experience across multiple regulated industries, including biopharmaceutical, petrochemical, and oil and gas. She specializes in business systems design and implementation and program and project management. Prior to Atara, Amy held a variety of roles at companies such as Seqirus and Amgen. She has also worked in Operations Management Consulting for companies such as KBC Advanced Technologies and Plant Leadership Systems. She earned her BS in Chemical Engineering from Arizona State University.